================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (date of earliest event reported): MAY 15, 2007
(Exact name of registrant as specified in its charter)
DELAWARE 000-31617 33-0595156
-------- --------- ----------
(State or other jurisdiction (Commission File (I.R.S. Employer
of incorporation) Number) Identification No.)
6611 DUMBARTON CIRCLE, FREMONT, CALIFORNIA 94555
------------------------------------------ -----
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (510) 505-2100
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
================================================================================
ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS;
APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF
CERTAIN DIRECTORS
(C) Effective May 16, 2007, Mr. Steve Lundy will be appointed Senior Vice
President of Sales and Marketing of Ciphergen Biosystems, Inc.
("Ciphergen"). Mr. Lundy's annual compensation is expected to be $230,000
with an annual bonus plan and a grant of stock options. Mr. Lundy joins
Ciphergen from GeneOhm, a division of Becton, Dickinson and Company ("BD")
Diagnostics, where he served as Vice President of Sales and Marketing
since 2003. At GeneOhm, Mr. Lundy successfully led the commercial launch
of several novel molecular diagnostic assays including the first molecular
test for Methicillin Resistant Staphylococcus Aureus ("MRSA"). From 2002
to 2003, Mr. Lundy served as Vice President of Marketing for Esoterix,
Inc. ("Esoterix"), which was acquired by Laboratory Corporation of
America, and led the commercial integration and re-branding of the
numerous reference labs acquired by Esoterix. Prior to Esoterix, he served
as Marketing Director for Molecular Diagnostics and Critical Care Testing
at Bayer Diagnostics Corporation, and had marketing responsibility for a
$100 million of business in the fastest growing business segments.
Mr. Lundy has no family relationship with any director or executive
officer of Ciphergen.
The press release is attached as Exhibit 99.1 to this Form 8-K.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d) EXHIBITS.
EXHIBIT
NUMBER DESCRIPTION
---------------- --------------------------------------------------------------
99.1 Mr. Steve Lundy Appointment Press Release Issued by Ciphergen
Biosystems, Inc. on May 15, 2007
-1-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
CIPHERGEN BIOSYSTEMS, INC.
Date: May 15, 2007 /s/ Debra A. Young
---------------------------------------
Debra A. Young
Vice President and Chief Financial
Officer
(Principal Financial and Accounting
Officer)
-2-
- 2 -